Abstract: Embodiments of the present invention relate to methods, compositions and kits for quantifying exosomes. In particular, methods, composition and kits that utilize lectins to quantify exosomes are provided.

Abstract: Methods, devices and systems for capturing biomarkers are provided. In particular, methods, compositions, and systems that utilize affinity capture devices comprising a processing chamber, affinity capture agent and porous membrane are provided.

Abstract: Methods, devices and systems for capturing biomarkers are provided. In particular, methods, compositions, and systems that utilize affinity capture devices comprising a processing chamber, affinity capture agent and porous membrane are provided.

Abstract: Methods, devices and systems for capturing biomarkers are provided. In particular, methods, compositions, and systems that utilize affinity capture devices comprising a processing chamber, affinity capture agent and porous membrane are provided.

Abstract: The present invention relates to a method for using lectins that bind to pathogens having surface glycoproteins or fragments thereof which contain glycoproteins, to remove them from infected blood or plasma or other fluids in an extracorporeal setting. Accordingly, the present invention provides a methods and devices for reducing viral load or plaque forming units in blood or plasma from one or more infected individuals. A preferred embodiment of the method comprises passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are disposed proximate to the membrane, collecting pass-through blood or plasma and optionally reinfusing the pass-through blood or plasma into the individual. Additionally, the present invention provides a methods and devices for the reduction of plaque forming units, cleared more rapidly and more efficiently than overall viral load.

Abstract: Provided herein is a method of and system for providing a software-as-a-service platform comprising implementing a mobile client application build phase to enable a developer-user to build a mobile client application; implementing, with a server computer, a mobile client application run phase to enable an end-user of the mobile client application to download and execute the mobile client application on a mobile device; and implementing a mobile client application manage phase to enable a manager-user to manage and analyze the usage of the mobile client application by the end-user.

Abstract: Methods, devices and systems for capturing biomarkers are provided. In particular, methods, compositions, and systems that utilize affinity capture devices comprising a processing chamber, affinity capture agent and porous membrane are provided.

Abstract: Provided herein is a method of and system for providing a software-as-a-service platform comprising implementing a mobile client application build phase to enable a developer-user to build a mobile client application; implementing, with a server computer, a mobile client application run phase to enable an end-user of the mobile client application to download and execute the mobile client application on a mobile device; and implementing a mobile client application manage phase to enable a manager-user to manage and analyze the usage of the mobile client application by the end-user.

Abstract: Embodiments of the present invention relate to methods, compositions and kits for quantifying exosomes. In particular, methods, composition and kits that utilize lectins to quantify exosomes are provided.

Abstract: Methods, devices and systems for capturing biomarkers are provided. In particular, methods, compositions, and systems that utilize affinity capture devices comprising a processing chamber, affinity capture agent and porous membrane are provided.

Abstract: The present invention relates to a method for using lectins that bind to pathogens having surface glycoproteins or fragments thereof which contain glycoproteins, to remove them from infected blood or plasma or other fluids in an extracorporeal setting. Accordingly, the present invention provides a methods and devices for reducing viral load or plaque forming units in blood or plasma from one or more infected individuals. A preferred embodiment of the method comprises passing the blood or plasma through a porous hollow fiber membrane wherein lectin molecules are disposed proximate to the membrane, collecting pass-through blood or plasma and optionally reinfusing the pass-through blood or plasma into the individual. Additionally, the present invention provides a methods and devices for the reduction of plaque forming units, cleared more rapidly and more efficiently than overall viral load.

Abstract: An extracorporeal fluid treatment apparatus includes a separator comprising a cartridge surrounding a porous separation membrane. The membrane separates a main flow path of a cellular component of the blood from a plasma flow path. An affinity medium is disposed within the plasma flow path to bind contaminants such as viral pathogens or toxins contained within the plasma. A pump pumps the plasma through the affinity medium at an assisted flow rate preferably between 10% and 40% of the whole blood flow rate. The assisted flow rate is selected to reduce a T90% of the apparatus by at least 50% as compared to a T90% of the apparatus without the plasma pump. A method of treating blood containing contaminants includes supplying infected blood to a separator and pumping the plasma component through an affinity medium at an assisted flow rate to increase contaminant clearance.